Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)

Table 2 Total dose for concurrent EBRT with [¹⁷⁷Lu]Lu-PSMA-617, estimated for various tumour locations and for various [¹⁷⁷Lu]Lu-PSMA activity levels

Tumour dose in Gy (EQD2)	EBRT	3 GBq [¹⁷⁷Lu]Lu-PSMA-617			6 GBq [¹⁷⁷Lu]Lu-PSMA-617			9 GBq [¹⁷⁷Lu]Lu-PSMA-617
Tumour location	Alone	Alone	Sum	+ 6%	Alone	Sum	+ 6%	Alone	Sum	+ 6%
Primary tumour	80	6	86	91	12	92	98	18	98	104
Macroscopic nodes in boost field	56	9	65	69	18	74	78	27	83	88
Microscopic nodes in elective field	47		56	59		65	69		74	78
Microscopic lesions outside fields	0		9	9		18	18		27	27

Values are expressed in Gy (EQD2), calculated with α/β = 3 for (metastatic) prostate cancer. The column marked + 6% includes an assumed synergistic effect for tumour locations that receive dose from the combined treatments
Lu-PSMA Lutetium PSMA, PSMA Prostate specific membrane antigen

ISSN: 1471-2407